Background: Hippocampal sclerosis (HpScl) in the elderly is often associated with neurodegeneration.
H ippocampal sclerosis (HpScl) is a pathologic diagnosis characterized by selective neuronal loss and gliosis without cystic cavitation in the subiculum and hippocampal CA1 sector. 1 The reported prevalence of HpScl in the elderly is 3% to 13%. 2 Although earlier thought to be related to hypoxic/ischemic damage to the hippocampus, 3 more recently it has been associated with neurodegenerative processes. 2, 4, 5 It is found in over 75% of cases of frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43) inclusions (FTLD-TDP). 6 HpScl can be difficult to detect pathologically in the setting of Alzheimer disease (AD) because of neurofibrillary degeneration in the same neuroanatomic distribution. It can only be diagnosed confidently when neuronal loss is disproportionate to the density of neurofibrillary tangles (NFTs), in particular, the presence of extracellular NFTs. 1 In AD, 31% of those with TDP-43 pathology have HpScl, whereas HpScl occurs in only 4% of AD cases negative for TDP-43. 2 Progranulin (GRN) mutations cause FTLD with ubiquitin-positive inclusions (FTLD-U) with TDP-43 pathology. [7] [8] [9] The mutations produce null alleles, causing approximately 50% decrease in progranulin expression. 10 In addition to causative mutations, Rademakers et al 11 reported on a common variant in the 3 0 untranslated region (3 0 UTR) of GRN (single-nucleotide polymorphism rs5848), in a putative microRNA binding site, and found that the Tallele was associated with increased risk of FTLD-U and with decreased progranulin protein levels in the brain, probably because of translational repression mediated by the microRNA. Analysis of 2 predominantly clinical FTLD case-control series, however, failed to identify a significant association with rs5848. 12, 13 Interestingly, a recent study explored the frequency of rs5848 in 644 autopsy-confirmed AD cases with respect to the presence of HpScl (n=57) and TDP-43 pathology. 14 In that study, the rs5848 T-allele was over-represented in AD with HpScl compared with those without HpScl. This finding suggested that a reduced progranulin level through rs5848 may be a risk factor for HpScl.
In a consecutive autopsy series of dementia patients followed prospectively at Mayo Clinic in Jacksonville, we describe the frequency, as well as the clinical and pathologic features, of cases with HpScl, and their association with genetic variants in GRN and apolipoprotein E (APOE ).
METHODS

Study Subjects and Clinical Review
In the time period of 1997 to 2008, 221 patients who had been prospectively evaluated at Mayo Clinic in Jacksonville by a behavioral neurologist (N.R.G.R.) came to autopsy. Most patients were followed longitudinally. Of these 221 cases, 13 did not have a diagnosis of dementia and 3 had Creutzfeldt-Jakob disease, all of which were excluded from this study. Of the remaining 205 cases, 43% were women and the median age of death was 79 years (range: 37 to 99 y). There were 28 cases with HpScl, and their 
Pathologic and Genetic Analyses
The brains were evaluated in a systematic and standardized manner as described earlier. 15 The protocol included freezing one-half of the brain and histologic evaluation of the other (usually left) half. Sections from frontal, temporal, parietal, and occipital cortices, hippocampus, amygdala, basal ganglia, thalamus, midbrain, pons, medulla, and cerebellum were examined with hematoxylin and eosin. Sections of cortex, hippocampus, amygdala, basal ganglia, and cerebellum were studied with thioflavin-S fluorescent microscopy, and the density of senile plaques and NFT was recorded in these sections. Sections were also processed with immunohistochemistry for ubiquitin, 16 phospho-tau, 17 TDP-43, 18 and fused in sarcoma, 19 as indicated. We screened for the presence of TDP-43-positive pathology in all cases in a section of medial temporal lobe that contained hippocampus, parahippocampal gyrus, occipitotemporal gyrus, and inferior temporal gyrus. If present, additional sections were studied, including midfrontal cortex, amygdala, basal ganglia, midbrain, and medulla. TDP-43-positive cases were subclassified as reported earlier, 20 using a scheme originally devised by Mackenzie and colleagues. 21 A Braak NFT stage 22 was assigned to all cases based upon the distribution of NFTs with thioflavin-S fluorescent microscopy. We considered cases with frequent neuritic plaques and a Braak NFT stage greater than III as having AD 23 regardless of other concurrent pathologic processes. All cases were screened for Lewy bodies in the amygdala/ basal forebrain with a-synuclein immunohistochemistry. 24 FTLD-U was diagnosed if there was evidence of neuronal loss, gliosis, and spongiosis in frontal and temporal cortices, ubiquitin-positive intraneuronal inclusions, and abnormal neurites. 25 Presence of HpScl was diagnosed if neuronal loss and gliosis was selective for CA1 and/or the subiculum in the absence of other pathologic findings that could account for neuronal loss in this region. In cases with NFTs, the degree of neuronal loss and gliosis had to be disproportionate to the density of NFTs, especially extracellular NFTs. 1 GRN rs5848 single-nucleotide polymorphism and APOE genotyping was performed on all cases with available DNA from frozen brain using ABI Taqman assays as described earlier. 10, 11 
Statistical Analyses
Thirteen cases did not have precise ages of onset in which case our best estimates were used for summaries. Importantly, for all of the HpScl cases, there was no uncertainty regarding whether ages of onset were above or below 75 years. Fisher exact test was used to assess simple associations, and exact binomial confidence intervals (CIs) were constructed for selected proportions. The Mann-Whitney U test was used to compare age of death according to the presence of HpScl. Logistic regression was used to estimate odds ratios with 95% CIs and to obtain P values to summarize the strength of evidence for associations. No adjustments were made for multiple testing in these exploratory analyses.
RESULTS
Frequency of HpScl
In this consecutive autopsy series of 205 dementia patients, 28 had HpScl (14%, 95% CI: 9%-19%), and 25 of the 28 cases (89%; 95% CI: 72%-98%) had TDP-43positive inclusions. The 3 cases that were TDP-43-negative all had onset before the age of 75 years. One had fused in sarcoma-positive inclusions, 1 had significant cerebrovascular disease as well as Lewy body disease and AD, and the third had severe AD with pallidonigral degeneration. HpScl was present in 65% (14 of 22) of cases with FTLD-U, 22% (10 of 45) of AD cases with TDP-43 pathology, and 2% (2 of 112) of AD cases without TDP-43 pathology. HpScl was present in 37% (25 of 68) of all cases with TDP-43 pathology. Patients with HpScl had a later age at death (median 83 years versus 79 years, P=0.005). The observed frequency of HpScl among those with age of onset greater than 75 years was 21% (11 of 53) compared with 11% (17 of 152) in those with age of onset less than 75 years although not statistically significant (P=0.1).
Clinical Features of HpScl
The HpScl cases with TDP-43 pathology were divided into 2 groups-onset before and after the age of 75 years. For those with onset before the age of 75 years (n=14), 6 presented with features of frontotemporal dementia with personality change and executive dysfunction (n=1), language difficulty (n=3), or both (n=2); 7 had predominant amnestic features that were clinically diagnosed with AD; and 1 had visual hallucinations and parkinsonism consistent with clinically probable dementia with Lewy bodies. All patients with a clinical diagnosis of frontotemporal dementia had autopsy findings consistent with FTLD-U, and those with clinically probable AD had pathologic findings consistent with AD, often with mixed pathology such as Lewy bodies or vascular disease. For cases presenting after the age of 75 years (n=11), 8 had an amnestic syndrome and were diagnosed with clinically probable AD. Of these 8 cases with clinically probable AD, 2 had pathologic findings of AD, but the remaining 6 did not meet criteria for high probability AD (Braak stage III or less), and all were TDP-43 positive. The amnestic patients not meeting AD pathologic criteria included 4 with FTLD-U, 1 with diffuse Lewy body disease, and 1 with no other significant pathology ("pure HpScl") ( Tables 1 and 2 ). However, we have used a Fisher exact test to compare the proportions of patients with pathologic AD in those with clinical diagnosis of AD and having HpScl in those with age of onset above and below 75 years and found a significant difference (Table 3) .
TDP-43 Pathology and Genetic Findings
HpScl has been reported to occur frequently in autopsy patients having FTLD-U and in AD with TDP-43. 2, [4] [5] [6] We compared the frequency of TDP-43 positivity in cases with HpScl with those of without. We found 25 of 28 (89%) with HpScl were TDP-43 positive, compared with 43 of 177 (24%) HpScl-negative patients, a highly significant difference (P<0.001).
Patients with GRN mutations have low levels of progranulin and at autopsy have TDP-43 pathology. 8 It has been found that the T-allele of rs5848 in the GRN 3 0 UTR is associated with decreased progranulin expression. 11 To study whether rs5848 is associated with HpScl, we analyzed rs5848 in patients with HpScl (n=25 after excluding 2 cases with GRN mutations and 1 with no sample) and controls without HpScl (n=176, excluding 1 with no sample). Assuming additive dosage for the T-allele in a logistic regression model, we identified significant association (P<0.001) with an estimated odds ratio associated with each copy of the T-allele of 3.0 (95% CI: 1.5-5.8) ( Table 4 ). Although the frequency of the APOE e4 allele was lower in cases with HpScl (11 of 26, 42%, 2 with no samples) than those without (102 of 176, 58%, 1 with no sample), this was not statistically significant (P=0.14).
DISCUSSION
In this consecutive series of elderly patients with dementia who came to autopsy from 1997 to 2008, HpScl was detected in 14% of the cases, which makes this a common pathologic finding most often associated with other pathologic processes. However, this study population consisted of patients referred to a tertiary center; therefore, cannot fully represent the general random elderly population with dementia due to selection bias. This may explain why the frequency in our study is slightly higher than reported in community-based sample which is between 3% and 13% 2 . Several published studies have shown that patients with HpScl in the elderly tend to have a later onset than those without HpScl. 2, 26, 27 This is also the case in this series. In patients with symptom onset 75 years of age or later, 21% (11 of 53) had HpScl at autopsy compared with 11% (17 of 152) of those with onset before 75 years of age. There was a high concordance between clinical diagnosis and pathologic diagnosis of HpScl patients with onset before the age of 75 years (eg, behavioral or language features associated with FTLD-U pathology, and amnestic features with AD pathology). In those whose dementia began after the age of 75 years, the most common clinical presentation was that of probable AD (8 of 11), but pathologically most cases (6 of 8) did not have sufficient NFTs to warrant a diagnosis of AD (Braak stage III or less) and actually had FTLD-U in most cases (4 of 6). This suggests that FTLD-U presenting with an amnestic syndrome should be in the differential diagnosis of patients having late onset (Z75 y) clinical probable AD. None of these FTLD-U cases had significant vascular disease at autopsy or clinical history of cardiac arrest, which makes hypoxic/ischemic cause of HpScl unlikely. These findings have important implications on patient management and in genetic studies in late onset dementia that use cases with clinically probable AD without ancillary methods (eg, yDiffuse Lewy body disease with atypical AD and cerebral amyloid angiopathy.
JOne diffuse Lewy body disease with mixed vascular pathology and 1 "pure HpScl." AD indicates Alzheimer disease; FTLD-U, frontotemporal lobar degeneration with ubiquitin-positive inclusions; HpScl, hippocampal sclerosis; TDP-43, TAR DNA-binding protein 43. cerebrospinal fluid analyses for Ab and tau 28 ) to exclude FTLD-U.
Not surprisingly, 89% (25 of 28) of the HpScl cases were positive for TDP-43 inclusions. Other studies have shown that HpScl occurs in 75% of TDP-43-positive FTLD-U cases, 6 and in those with both AD and TDP-43 pathology, 31% have HpScl, whereas in those with AD only HpScl occurs in 4%. 2 In our series, HpScl is present in 64% (14 of 22) of cases with FTLD-U, 22% (10 of 45) of AD cases with TDP-43 pathology, and 2% (2 of 112) of AD cases without TDP-43 pathology. HpScl was also present in 37% (25 of 68) of all dementia cases with TDP-43 inclusions. We find that TDP-43 pathology is highly associated with HpScl in our group which suggests that TDP-43 has a strong association with HpScl in neurodegenerative diseases.
GRN mutations may cause TDP-43 pathology. [7] [8] [9] The mutations produce null alleles, and cause at least 50% decrease in progranulin expression. Progranulin expression in the brain is also associated with a common variant in the 3 0 UTR of GRN, in a putative microRNA binding site. 11 In a recent study of HpScl in a series of 644 autopsy-confirmed AD, 57 had HpScl, and 72% of the HpScl cases carried a T-allele, whereas it was present in 51% of AD without HpScl (P=0.005). The results suggested that the T-allele may be a risk factor for HpScl in the elderly. 14 In our smaller autopsy series that included a mixture of neurodegenerative processes, including some cases of FTLD-U, there was also a statistically significant association of the T-allele with HpScl (P=0.008).
CONCLUSIONS
This consecutive autopsy series shows a 14% (28 of 205) prevalence of HpScl and its strong association with TDP-43 pathology. Ours is one of the first studies to emphasize that the patients with late onset (75 y of age or above) dementia who present with a predominantly amnestic syndrome similar to those of clinically probable AD can have FTLD-U with HpScl, not AD. Diagnostic accuracy was considerably better in those with early onset dementia. Presumably, the severe neuronal loss and gliosis in the medial temporal lobe structures is the correlate of the amnestic syndrome, and it suggests that medial temporal lobe structures may have been the initial focus of the pathologic process. It remains to be determined whether ancillary diagnostic methods, such as amyloid imaging or cerebrospinal fluid biomarkers, can differentiate FTLD-U with HpScl from AD in late onset dementia patients with predominant amnestic syndrome. Making this distinction may have a significant impact on genetic and treatment studies.
